No Decrease in the Rate of Early or Missed Colorectal Cancers After Colonoscopy With Polypectomy Over a 10-Year Period: A Population-Based Analysis

Background: Cervix, breast and colorectal cancers are included in the national population-based screening (PBS) program in Turkey. This study aimed to assess participation in PBSs for these cancers and to identify factors associated with participation in screenings in Safranbolu district of Karabuk, Turkey in 2016-2017. Methods: In this cross-sectional study, separate studying groups for cervix, breast and colorectal cancers were identified, taking into account the target age range specified in the national screening standards. The sample size was determined to be 374 for cervical cancer, 371 for breast cancer and 373 for colorectal cancer in the Epi-Info StatCalc program with a prevalence of 50%, a 95% Confidence Interval (CI) and a 5% error margin. The results of the data collected through face-to-face interview using questionnaires were evaluated with Chisquare tests (P<0.05) and included in the binary logistic regression model. Results: Participation in PBS at least once between 2011 and 2016 years was 26.2% for cervical cancer, 27.6% for breast cancer and 31.6% for colorectal cancer, whereas the level of PBS or opportunistic screening at least once was 51.1%, 42.7% and 32.2%, respectively. A 2.9-fold increase in participation for the cervical cancer screening was associated with informing women about cervical cancer by the family physicians. Being married and living in the district center showed associations with a higher rate of participation for colorectal cancer screening. Conclusion: Participation in PBS was low for the 5.5-year period. More effort is needed to increase the effectiveness of the program.

Download Full-text

Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study

Gut ◽

10.1136/gut.41.4.522 ◽

1997 ◽

Vol 41 (4) ◽

pp. 522-525 ◽

Cited By ~ 163

Author(s):

D Kornfeld ◽

A Ekbom ◽

T Ihre

Keyword(s):

Colorectal Cancer ◽

Ulcerative Colitis ◽

Primary Sclerosing Cholangitis ◽

Sclerosing Cholangitis ◽

Cumulative Risk ◽

Population Based ◽

Colorectal Cancers ◽

Population Based Study ◽

Increased Risk ◽

Swedish Cancer Registry

Background—Patients with ulcerative colitis have an increased risk of colorectal cancer. Duration, age, and extent of the disease at diagnosis are the only established risk factors. Patients with ulcerative colitis and concomitant primary sclerosing cholangitis (PSC) have been reported to have a higher frequency of colonic DNA aneuploidy and/or dysplasia than expected, findings indicating an increased risk of colorectal cancer compared with other patients with ulcerative colitis.Methods—A population based cohort consisting of 125 patients with a verified diagnosis of PSC was followed up by linkage to the Swedish Cancer Registry for the occurrence of colorectal cancer.Results—There were 12 colorectal cancers. Six cancers were diagnosed prior to the diagnosis of PSC. Among the 104 patients with an intact colon at the time of the diagnosis of PSC there was a cumulative risk for colorectal cancer of 16% after 10 years. Among the 58 patients with a diagnosis of ulcerative colitis and colorectal cancer prior to the diagnosis of PSC, there were five colorectal cancers corresponding to a cumulative risk of 25% after 10 years.Conclusions—Patients with ulcerative colitis and concomitant PSC seem to constitute a subgroup with a high risk for colorectal cancer.

Download Full-text

Socio-Economic and Geographical Disparities in Colorectal Adenomas and Colorectal Cancers Detection : a Population-Based Study

Annals of Oncology ◽

10.1093/annonc/mdt201.20 ◽

2013 ◽

Vol 24 ◽

pp. iv19

Author(s):

Isabelle Fournel ◽

Abderrahmane Bourredjem ◽

Erik André Sauleau ◽

Vanessa Cottet ◽

Anne Marie Bouvier ◽

...

Keyword(s):

Population Based ◽

Colorectal Adenomas ◽

Colorectal Cancers ◽

Population Based Study

Download Full-text

528 CHARACTERISTICS AND SURVIVAL OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND POST-COLONOSCOPY COLORECTAL CANCERS: A POPULATION-BASED COHORT STUDY

Gastroenterology ◽

10.1016/s0016-5085(21)01002-7 ◽

2021 ◽

Vol 160 (6) ◽

pp. S-107-S-108

Author(s):

Frederikke Sch⊘nfeldt Troelsen ◽

Henrik Toft S⊘rensen ◽

Seth Crockett ◽

Lars Pedersen ◽

Rune Erichsen

Keyword(s):

Inflammatory Bowel Disease ◽

Cohort Study ◽

Bowel Disease ◽

Population Based ◽

Colorectal Cancers ◽

Inflammatory Bowel

Download Full-text

Post-colonoscopy colorectal cancers identified by probabilistic and deterministic linkage: results in an Australian prospective cohort

BMJ Open ◽

10.1136/bmjopen-2018-026138 ◽

2019 ◽

Vol 9 (6) ◽

pp. e026138 ◽

Cited By ~ 3

Author(s):

Kavitha Subramaniam ◽

P W Ang ◽

Teresa Neeman ◽

Mitali Fadia ◽

Doug Taupin

Keyword(s):

Cohort Study ◽

Incidence Rate ◽

Prospective Cohort ◽

Cancer Registries ◽

International Classification Of Diseases ◽

Population Based ◽

Primary Outcome Measure ◽

Colorectal Cancers ◽

Diagnosis Codes ◽

Classification Of Diseases

ObjectivePost-colonoscopy colorectal cancers (PCCRCs) are recognised as a critical quality indicator. Benchmarking of PCCRC rate has been hampered by the strong influence of different definitions and methodologies. We adopted a rigorous methodology with high-detail individual data to determine PCCRC rates in a prospective cohort representing a single jurisdiction.SettingWe performed a cohort study of individuals who underwent colonoscopy between 2001 and 2008 at a single centre serving Australian Capital Territory (ACT) and enclaving New South Wales (NSW) region. These individuals were linked to subsequent colorectal cancer (CRC) diagnosis, within 5 years of a negative colonoscopy, through regional cancer registries and hospital records using probabilistic and deterministic record linkage. All cases were verified by pathology review. Predictors of PCCRCs were extracted.Participants7818 individuals had a colonoscopy in the cohort. Linkage to cancer registries detected 384 and 98 CRCs for notification dates of 2001–2013 (ACT) and 2001–2010 (NSW). A further 55 CRCs were identified from a search of electronic medical records using International Classification of Diseases-10 diagnosis codes. After verification and exclusions, 385/537 CRCs (58% male) were included.Primary outcome measurePCCRC rates.ResultsThere were 15 PCCRCs in our cohort. The PCCRC incidence rate was 0.384/1000 person-years and the 5-year PCCRC risk was estimated as 0.192% (95% CI 0.095 to 0.289). The index colonoscopy prior to PCCRC was more likely to show diverticulosis (p=0.017 for association, OR 3.56, p=0.014) and have poor bowel preparation (p=0.017 for association, OR 4.19, p=0.009).ConclusionIn this population-based cohort study, the PCCRC incidence rate was 0.384/1000 person-years and the 5-year PCCRC risk was 0.192%. These data show the ‘real world’ accuracy of colonoscopy for CRC exclusion.

Download Full-text

Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal Cancers

JCO Precision Oncology ◽

10.1200/po.17.00253 ◽

2018 ◽

pp. 1-10 ◽

Cited By ~ 3

Author(s):

Katerina Shulman ◽

Ofra Barnett-Griness ◽

Vered Friedman ◽

Joel K. Greenson ◽

Stephen B. Gruber ◽

...

Keyword(s):

Braf Mutation ◽

Median Overall Survival ◽

Population Based ◽

Disease Stage ◽

Colorectal Cancers ◽

P Value ◽

Wild Type ◽

First Line ◽

New Developments ◽

Israeli Population

Purpose Microsatellite instable-high (MSI-H) colorectal cancers (CRCs) are known to carry better survival in the local disease stage even without treatment. The influence of types of treatment on survival of MSI-H metastatic CRCs (mCRCs) is still unclear and is evaluated in this study. Materials and Methods Patients with MSI-H mCRC treated with first-line chemotherapy, with or without bevacizumab, identified in the Israeli population-based Molecular Epidemiology of Colorectal Cancer (MECC) study, were diagnosed between 1998 and 2013 and followed up until May 2017; MSI status was determined by comparing 10 markers in tumor and normal tissue. Dates of metastases and death and treatment details were extracted from oncology records. Results Among 590 patients treated for mCRC, 106 (18%) had MSI-H tumors. Patients with MSI-H had a median overall survival (OS, from start of first-line treatment) of 1.6 years. The presence of a somatic B-Raf proto-oncogene ( BRAF) mutation was a significant adverse prognostic factor in the MSI-H group (hazard ratio [HR], 1.8; 95% CI, 1.1 to 3.0; P = .026). MSI-H tumors without BRAF mutation (n = 87) had similar OS benefit from fluorouracil (FU) only as from any combination protocols (HR, 0.93; P = .78), whereas microsatellite-stable (MSS) tumors without BRAF mutation (n = 456) showed improved OS over FU-only regimens when combination chemotherapy with or without bevacizumab was used (HR, 0.58; P < .01; P value for interaction = .07). Patients with MSI-H/BRAF wild type (WT) had survival advantage over patients with MSS disease (adjusted HR, 0.58; 95% CI, 0.35 to 0.98) when treated with FU-only protocols. Conclusion Clinical outcomes differ substantially between patients with MSS/BRAF-WT mCRC and MSI-H/BRAF-WT mCRC, with measurable differences between chemotherapy regimens. MSI-H mCRCs are a clinically distinct subset of colorectal cancers. Their current poor outcome suggests that new clinical trials are needed to identify therapeutic options, potentially taking advantage of the new developments in the field of immunotherapy.

Download Full-text